Lori Taylor of Annexon Biosciences presented data on ANX007 for the treatment of geographic atrophy at Clinical Trials at the Summit in Park City, Utah. The data focus on the preservation of photoreceptors and retinal pigment epithelial cells in the foveal center, potentially explaining the visual acuity benefit seen with ANX007. The presentation highlighted the regional effects of ANX007 on RPE and photoreceptor loss. Taylor, as the senior vice president for portfolio strategy and operations at Annexon Biosciences, discussed the potential benefits of ANX007 in preserving retinal structure in areas that are crucial for visual acuity.
Source link
Annexon previews emerging data on ANX007 for geographic atrophy
